Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
Evommune, Inc. Investigation Details
Evommune Inc. stock dropped approximately 38% today after the Company disclosed that its Phase 2b trial of EVO756 in moderate-to-severe chronic spontaneous urticaria did not meet its primary endpoint.
EVO756 was Evommune's lead pipeline candidate. The Phase 2b trial measured mean change in UAS7 at 12 weeks in patients with moderate-to-severe CSU -- the trial did not achieve statistical significance on that primary endpoint. Evommune stated it intends to continue developing EVO756 in atopic dermatitis and migraine indications, but the CSU program represented a central component of the Company's near-term clinical strategy.EVO756 was Evommune's lead pipeline candidate. The Phase 2b trial measured mean change in UAS7 at 12 weeks in patients with moderate-to-severe CSU -- the trial did not achieve statistical significance on that primary endpoint. Evommune stated it intends to continue developing EVO756 in atopic dermatitis and migraine indications, but the CSU program represented a central component of the Company's near-term clinical strategy.
The stock decline followed a period in which Evommune's share price had reflected expectations around the CSU data readout. Investors who purchased EVMN shares leading up to the June 29, 2026 disclosure absorbed the full impact of today's single-session drop.
